title: Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care.
abstract: OBJECTIVE
  Adherence is essential to successful virologic outcome of highly active antiretroviral therapy (HAART). Documented factors contributing to poor adherence include toxicity, food requirements, and pill burden. Once-daily antiretroviral therapies for HIV infection offer potential benefit by decreasing pill burden and dosing frequency, which may subsequently improve treatment adherence. This Consensus Statement is intended to offer guidance to physicians actively involved in HIV/AIDS care.
  
  
  METHODS
  Eight physicians with expertise in HIV medicine were invited by the International Association of Physicians in AIDS Care (IAPAC) to serve on an ad hoc Advisory Committee.
  
  
  METHODS
  IAPAC convened the Advisory Committee in June 2002 to develop a draft Consensus Statement. Scientific and clinical research, and other data in published literature and abstracts from scientific conferences were considered by strength of evidence. A Subcommittee updated the Consensus Statement in October 2002 to reflect relevant data presented at the XIV International AIDS Conference and the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. This document represents consensus agreement of the Advisory Committee. CONFLICT OF INTEREST DISCLOSURE: The International Association of Physicians in AIDS Care sponsored and coordinated the development of this Consensus Statement with an unrestricted educational grant from Bristol-Myers Squibb. The opinions expressed in this Consensus Statement represent only those of the Advisory Committee.
authors.affiliation: CRI New England, 23 Miner Street, Boston, Massachusetts 02215-3318, USA.
authors.forename: Calvin
authors.initials: C
authors.lastname: Cohen
authors.forename: Richard A
authors.initials: RA
authors.lastname: Elion
authors.forename: Ian
authors.initials: I
authors.lastname: Frank
authors.forename: Patricia
authors.initials: P
authors.lastname: Kloser
authors.forename: Renslow
authors.initials: R
authors.lastname: Sherer
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Squires
authors.forename: Corklin
authors.initials: C
authors.lastname: Steinhart
authors.forename: Pablo
authors.initials: P
authors.lastname: Tebas
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance; D019562:Viral Load
chemical_list: D044966:Anti-Retroviral Agents